Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.52 |
| ▸ | ADH1C | P00326 | 1/20 | 0.52 |
| ▸ | ADH1A | P07327 | 1/20 | 0.52 |
| ▸ | ADH4 | P08319 | 1/20 | 0.52 |
| ▸ | ADH7 | P40394 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277270 | 0.97 | ADH1B (0.54) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL277135 | 0.94 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL16223598 | 0.94 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4660468 | 0.94 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4603730 | 0.94 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL14142731 | 0.94 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL3689236 | 0.94 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL570864 | 0.94 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1203435 | 0.94 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL726335 | 0.94 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ADH1B 3094/4885ADH1C 4321/4885ADH1A 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.